Aldeyra Therapeutics

ALDX

Market cap $298M

Overview Fund Activity

4.96 USD

-0.13

2.55%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

4.96

0.00

0%

1 day

-2.55%

5 days

-14.63%

1 month

-8.82%

3 months

64.24%

6 months

-21.39%

Year to date

-4.98%

1 year

-16.07%

5 years

-30.24%

10 years

-27.7%

About: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.

Employees: 8

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,258% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $103K

47% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 32

2% less funds holding

Funds holding: 125 [Q1] → 122 (-3) [Q2]

6.24% less ownership

Funds ownership: 63.45% [Q1] → 57.21% (-6.24%) [Q2]

13% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 24

42% less capital invested

Capital invested by funds: $226M [Q1] → $131M (-$94.3M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

See Fund Rankings

Financial journalist opinion

Based on 3 articles about ALDX published over the past 30 days

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025. Dr. Brady's conversation with Matthew Caufield, Director, Eq.

Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of primary large B-Cell lymphomas of immune-privileged sites, including primary vitreoretinal lymphoma. There is currently no approved treatment for patients with primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer that affects appr.

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmen.

Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025. Dr. Brady's conversation with Matthew Caufield, Director, E.

Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the European Medicines Agency (EMA) has granted Orphan Designation for ADX-2191 (methotrexate intravitreal injection) for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa. There are currently no approved drug treatments for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characteriz.

Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmitted New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025. “Based on the FDA's requirement f.

Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Zacks Investment Research

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Zacks Investment Research

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aldeyra Therapeutics (ALDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Aldeyra Therapeutics' Reproxalap is now on its third NDA, which was filed in June 2025. It supposedly fixes prior trial flaws. ALDX believes a potential FDA acceptance could set a PDUFA date for December 2025. After that, AbbVie may pay $100 million upfront and share US profits if Reproxalap wins approval, which should materially de-risk its eventual commercialization.

Aldeyra Therapeutics: Pivotal FDA Decision After Reproxalap's Chamber Data

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration (FDA) for ADX-2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently lacking FDA-approved therapy. “Primary vitreoretinal lymphoma is treated today off label with intravitre.

Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

See News Rankings

Charts implemented using Lightweight Charts™